Steven Cohen Immunovant, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $38.8 Million - $56.2 Million	-1,283,073 Reduced 48.11%	1,383,810 $44.7 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $83.5 Million - $118 Million	2,666,883 New	2,666,883 $112 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $6.5 Million - $10.9 Million	457,467 New	457,467 $8.68 Million
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $6.65 Million - $8.59 Million	-435,751 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$6.59 - $17.75 $10.1 Million - $27.2 Million	-1,531,549 Reduced 77.85%	435,751 $7.73 Million
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $7.73 Million - $12.5 Million	1,967,300 New	1,967,300 $11 Million
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $1.55 Million - $2.6 Million	-459,300 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $2.23 Million - $3.87 Million	-441,200 Reduced 49.0%	459,300 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $6.6 Million - $8.39 Million	900,500 New	900,500 $7.67 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $1.77 Million - $3.17 Million	-187,900 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $922,140 - $3.5 Million	-70,500 Reduced 27.28%	187,900 $3.01 Million
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $45.6 Million - $66.1 Million	-1,254,866 Reduced 82.92%	258,400 $11.9 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $30.8 Million - $53 Million	1,363,623 Added 911.25%	1,513,266 $53.3 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $1.75 Million - $3.59 Million	126,251 Added 539.72%	149,643 $3.64 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $195,557 - $400,704	23,392 New	23,392 $364,000

Others Institutions Holding IMVT

# of Institutions

220

Shares Held

65.1M

Call Options Held

697K

Put Options Held

629K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account